Cytosorbents (CTSO) Common Equity (2010 - 2026)

Cytosorbents (CTSO) has reported Common Equity for 17 consecutive years, with -$751000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 106.48% year-over-year to -$751000.0; the trailing twelve-month figure through Jun 2026 stood at -$751000.0 (down 106.48% YoY), and the FY2025 full-year result was $5.9 million, down 46.85% from the prior year.
• Common Equity retreated to -$751000.0 in Q2 2026 per CTSO's latest filing, from $2.2 million in the prior quarter.
• Across five years, Common Equity topped out at $55.4 million in Q1 2022 and bottomed at -$751000.0 in Q2 2026.
• Historically, Common Equity has averaged $21.0 million across 5 years, with a median of $18.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Common Equity retreated 25.89% in 2025, then slumped 106.48% in 2026.
• Over 5 years, Common Equity stood at $35.4 million in 2022, then plunged by 33.63% to $23.5 million in 2023, then slumped by 52.7% to $11.1 million in 2024, then slumped by 46.85% to $5.9 million in 2025, then slumped by 112.72% to -$751000.0 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$751000.0, $2.2 million, and $5.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.